Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HLA-B*14:02-Restricted Env-Specific CD8+ T-Cell Activity Has Highly Potent Antiviral Efficacy Associated with Immune Control of HIV Infection.
Leitman EM, Willberg CB, Tsai MH, Chen H, Buus S, Chen F, Riddell L, Haas D, Fellay J, Goedert JJ, Piechocka-Trocha A, Walker BD, Martin J, Deeks S, Wolinsky SM, Martinson J, Martin M, Qi Y, Sáez-Cirión A, Yang OO, Matthews PC, Carrington M, Goulder PJR. Leitman EM, et al. J Virol. 2017 Oct 27;91(22):e00544-17. doi: 10.1128/JVI.00544-17. Print 2017 Nov 15. J Virol. 2017. PMID: 28878089 Free PMC article. Clinical Trial.
Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.
Chéret A, Nembot G, Mélard A, Lascoux C, Slama L, Miailhes P, Yeni P, Abel S, Avettand-Fenoel V, Venet A, Chaix ML, Molina JM, Katlama C, Goujard C, Tamalet C, Raffi F, Lafeuillade A, Reynes J, Ravaux I, Hoën B, Delfraissy JF, Meyer L, Rouzioux C; OPTIPRIM ANRS Study Group. Chéret A, et al. Lancet Infect Dis. 2015 Apr;15(4):387-96. doi: 10.1016/S1473-3099(15)70021-6. Epub 2015 Feb 18. Lancet Infect Dis. 2015. PMID: 25701561 Clinical Trial.
Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug-Resistant Human Immunodeficiency Virus Type 2 Infection.
Bachelard A, Le Hingrat Q, Ferré VM, Lê M, Peytavin G, Damond F, Charpentier C, Fremont Goudot G, Goupil de Bouille J, Lariven S, Delobel P, Yazdanpanah Y, Descamps D, Matheron S, Ghosn J; ANRS CO05 VIH-2 cohort study group. Bachelard A, et al. Clin Infect Dis. 2024 Apr 10;78(4):1005-1010. doi: 10.1093/cid/ciad695. Clin Infect Dis. 2024. PMID: 38630945
Nonreactive Human Immunodeficiency Virus Type 1 Rapid Tests After Sustained Viral Suppression Following Antiretroviral Therapy Initiation During Primary Infection.
Stefic K, Novelli S, Mahjoub N, Seng R, Molina JM, Cheneau C, Barin F, Chaix ML, Meyer L, Delaugerre C; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) PRIMO Study Group. Stefic K, et al. J Infect Dis. 2018 May 5;217(11):1793-1797. doi: 10.1093/infdis/jiy120. J Infect Dis. 2018. PMID: 29509924
HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype.
Sáez-Cirión A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F, Barré-Sinoussi F, Delfraissy JF, Sinet M, Pancino G, Venet A; Agence Nationale de Recherches sur le Sida EP36 HIV Controllers Study Group. Sáez-Cirión A, et al. Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6776-81. doi: 10.1073/pnas.0611244104. Epub 2007 Apr 11. Proc Natl Acad Sci U S A. 2007. PMID: 17428922 Free PMC article.
Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses.
Sáez-Cirión A, Sinet M, Shin SY, Urrutia A, Versmisse P, Lacabaratz C, Boufassa F, Avettand-Fènoël V, Rouzioux C, Delfraissy JF, Barré-Sinoussi F, Lambotte O, Venet A, Pancino G; ANRS EP36 HIV Controllers Study Group. Sáez-Cirión A, et al. J Immunol. 2009 Jun 15;182(12):7828-37. doi: 10.4049/jimmunol.0803928. J Immunol. 2009. PMID: 19494307
117 results